Svetlana A. Shestopal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Svetlana A. Shestopal has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Andrey G. Sarafanov
Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA
4 shared publications - Haarin Chun
Center for Biologics Evaluation and Research, U. S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA
3 shared publications - Philip Olivares
Center for Biologics Evaluation and Research, U. S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA
3 shared publications - Ekaterina S. Marakasova
Center for Biologics Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA
2 shared publications - James H. Kurasawa
Center for Biologics Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA
2 shared publications - Ally K. Smith
Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA
1 shared publication
Latest Publications
- Open Access
- 23 July 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (15) , 8134
Isolated Variable Domains of an Antibody Can Assemble on Blood Coagulation Factor VIII into a Functional Fv-like Complex
Single-chain variable fragments (scFv) are antigen-recognizing variable fragments of antibodies (FV) where both subunits (VL and VH) are connected via an artificial linker. One particular scFv, iKM33, directed against blood coagulation factor VIII (FVIII) was shown to inhibit major FVIII functions and is useful in FVIII research. We aimed to investigate the properties of iKM33 enabled with protease-dependent disintegration. Three variants of iKM33 bearing thrombin cleavage sites within the linker were expressed using a baculovirus system and purified by two-step chromatography. All proteins retained strong binding to FVIII by surface plasmon resonance, and upon thrombin cleavage, dissociated into VL and VH as shown by size-exclusion chromatography. However, in FVIII activity and low-density lipoprotein receptor-related protein 1 binding assays, the thrombin-cleaved iKM33 variants were still inhibitory. In a pull-down assay using an FVIII-affinity sorbent, the isolated VH, a mixture of VL and VH, and intact iKM33 were carried over via FVIII analyzed by electrophoresis. We concluded that the isolated VL and VH assembled into scFv-like heterodimer on FVIII, and the isolated VH alone also bound FVIII. We discuss the potential use of both protease-cleavable scFvs and isolated Fv subunits retaining high affinity to the antigens in various practical applications such as therapeutics, diagnostics, and research.
- 23 July 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (15) , 8134
Open AccessIsolated Variable Domains of an Antibody Can Assemble on Blood Coagulation Factor VIII into a Functional Fv-like Complex
Single-chain variable fragments (scFv) are antigen-recognizing variable fragments of antibodies (FV) where both subunits (VL and VH) are connected via an artificial linker. One particular scFv, iKM33, directed against blood coagulation factor VIII (FVIII) was shown to inhibit major FVIII functions and is useful in FVIII research. We aimed to investigate the properties of iKM33 enabled with protease-dependent disintegration. Three variants of iKM33 bearing thrombin cleavage sites within the linker were expressed using a baculovirus system and purified by two-step chromatography. All proteins retained strong binding to FVIII by surface plasmon resonance, and upon thrombin cleavage, dissociated into VL and VH as shown by size-exclusion chromatography. However, in FVIII activity and low-density lipoprotein receptor-related protein 1 binding assays, the thrombin-cleaved iKM33 variants were still inhibitory. In a pull-down assay using an FVIII-affinity sorbent, the isolated VH, a mixture of VL and VH, and intact iKM33 were carried over via FVIII analyzed by electrophoresis. We concluded that the isolated VL and VH assembled into scFv-like heterodimer on FVIII, and the isolated VH alone also bound FVIII. We discuss the potential use of both protease-cleavable scFvs and isolated Fv subunits retaining high affinity to the antigens in various practical applications such as therapeutics, diagnostics, and research.
- Open Access
- 10 July 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (10) , 2255-2269
Characterization of interaction between blood coagulation factor VIII and LRP1 suggests dynamic binding by alternating complex contacts
- 10 July 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (10) , 2255-2269
Open AccessCharacterization of interaction between blood coagulation factor VIII and LRP1 suggests dynamic binding by alternating complex contacts
- Open Access
- 1 July 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 297 (1) , 100842
Molecular chaperone RAP interacts with LRP1 in a dynamic bivalent mode and enhances folding of ligand-binding regions of other LDLR family receptors
- 1 July 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 297 (1) , 100842
Open AccessMolecular chaperone RAP interacts with LRP1 in a dynamic bivalent mode and enhances folding of ligand-binding regions of other LDLR family receptors
- Open Access
- 1 July 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (30) , 22033-22041
Mapping the Binding Region on the Low Density Lipoprotein Receptor for Blood Coagulation Factor VIII
- 1 July 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (30) , 22033-22041
Open AccessMapping the Binding Region on the Low Density Lipoprotein Receptor for Blood Coagulation Factor VIII